KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Other Working Capital Changes (2016 - 2026)

Biocryst Pharmaceuticals filings provide 16 years of Other Working Capital Changes readings, the most recent being -$5.9 million for Q4 2025.

  • On a quarterly basis, Other Working Capital Changes fell 926.13% to -$5.9 million in Q4 2025 year-over-year; TTM through Sep 2025 was $5.3 million, a 353.75% increase, with the full-year FY2024 number at -$2.0 million, down 128.72% from a year prior.
  • Other Working Capital Changes hit -$5.9 million in Q4 2025 for Biocryst Pharmaceuticals, down from $5.9 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $9.8 million in Q1 2021 to a low of -$9.8 million in Q2 2021.
  • Median Other Working Capital Changes over the past 5 years was $107000.0 (2022), compared with a mean of $436350.0.
  • Biggest five-year swings in Other Working Capital Changes: plummeted 2688.64% in 2021 and later soared 7273.17% in 2023.
  • Biocryst Pharmaceuticals' Other Working Capital Changes stood at $826000.0 in 2021, then surged by 75.67% to $1.5 million in 2022, then plummeted by 148.93% to -$710000.0 in 2023, then grew by 19.15% to -$574000.0 in 2024, then crashed by 926.13% to -$5.9 million in 2025.
  • The last three reported values for Other Working Capital Changes were -$5.9 million (Q4 2025), $5.9 million (Q3 2025), and -$160000.0 (Q2 2025) per Business Quant data.